Collaboration and License Agreements - Amgen, Inc (Details) - Amgen Incorporated - Olpasiran Agreement |
Dec. 31, 2024
USD ($)
|
Sep. 30, 2016
agreement
|
|---|---|---|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Number of agreements | agreement | 2 | |
| Contract assets | $ 0 | |
| Contract liabilities | 0 | |
| Maximum | ||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Additional remaining development regulatory and sales milestones payments | $ 485,000,000 |
| X | ||||||||||
- Definition Additional remaining development regulatory and sales milestones payments. No definition available.
|
| X | ||||||||||
- Definition Number of agreements. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|